Fulgent Genetics completes $170M acquisition of Symphony Buyer via merger

Fulgent Genetics, Inc.

Total purchase price of approximately $170 million, subject to customary adjustments for closing cash, indebtedness, working capital, and expenses.
Acquisition closed on April 26, 2022; Symphony becomes wholly owned subsidiary of Fulgent Genetics.
Deal originally announced via merger agreement dated April 16, 2022; stockholders of Symphony consented to the merger.
Consideration includes upfront cash per share plus contingent rights to escrow and post-closing adjustments.
Merger was effected through merger of a Fulgent subsidiary (Merger Sub) into Symphony, with Symphony surviving.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.